The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSLN.L Regulatory News (SLN)

  • There is currently no data for SLN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Edison Investment Research Limited: Edison issues initiation on Silence Therapeutics (SLN)

9 Jan 2020 10:04

Edison Investment Research Limited Edison Investment Research Limited: Edison issues initiation on Silence Therapeutics (SLN) 09-Jan-2020 / 10:03 GMT/BST


 

London, UK, 9 January 2020

Edison issues initiation on Silence Therapeutics (SLN)

We are initiating coverage of Silence Therapeutics (SLN), a developer of siRNA drugs for diseases that can be genetically targeted. Silence has a proprietary platform for developing siRNA therapeutics, the strength of which was highlighted by preclinical development deals with Mallinckrodt and Takeda (details below). The company will also be re-entering the clinic in Q120 with SLN124, its own drug for iron overload. We are initiating with a valuation of £345m or 440p per share.

 

Our initial valuation of £345m or 440p per share is based on a risk-adjusted NPV analysis of the firm's assets and revenue streams and is driven primarily by our valuation of SLN124 (£141m). We forecast that it will require £105m in additional capital to reach profitability in 2026, offset by potential business development deals.

Click here to view the full report.

 

Subscribe to Edison's content to receive reports by email.

All reports published by Edison are free-to-access and available on the website.

 

About Edison: Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world-renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisers and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

Edison is authorised and regulated by the Financial Conduct Authority.

Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.

For more information please contact Edison:

Nathaniel Calloway, +1 646 653 7036

healthcare@edisongroup.com

 

Learn more at www.edisongroup.com and connect with Edison on:

LinkedIn https://www.linkedin.com/company/edison-group-

Twitter  www.twitter.com/Edison_Inv_Res

YouTube www.youtube.com/edisonitv


Dissemination of a CORPORATE NEWS, transmitted by EQS Group.The issuer is solely responsible for the content of this announcement.


End of Announcement - EQS News Service

949913 09-Jan-2020 

corporate announcement transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement.

Date   Source Headline
4th Jun 20148:32 amRNSNotice of AGM
7th May 20145:05 pmRNSHolding(s) in Company
7th May 201412:03 pmRNSHolding(s) in Company
29th Apr 20144:30 pmRNSResult of Placing
28th Apr 20145:21 pmRNSProposed Placing to raise a minimum of £10 million
28th Apr 20147:00 amRNSGene knockdown in non-human primates
19th Mar 20147:02 amRNSPotential Equity Fundraising
19th Mar 20147:00 amRNSPreliminary Results - Year Ended 31 December 2013
27th Feb 20147:00 amRNSYear end trading update
26th Feb 201412:09 pmRNSHolding(s) in Company
24th Feb 20143:41 pmRNSHolding(s) in Company
23rd Jan 201411:35 amRNSHolding(s) in Company
4th Dec 201311:39 amRNSHolding(s) in Company
22nd Nov 20134:00 pmRNSHolding(s) in Company
21st Nov 20136:25 pmRNSHolding(s) in Company
20th Nov 20135:00 pmRNSGrant of Options and Additional Listing
18th Nov 20137:02 amRNSInvestor Event and Appointment of NOMAD
18th Nov 20137:01 amRNSDirectorate and senior management changes
18th Nov 20137:00 amRNSNew Clinical Trial
8th Nov 20135:33 pmRNSHolding(s) in Company
5th Nov 20137:00 amRNSHolding(s) in Company
23rd Oct 20137:00 amRNSInvestor Day
17th Oct 20135:50 pmRNSHolding(s) in Company
17th Oct 20135:50 pmRNSHolding(s) in Company
17th Oct 20135:50 pmRNSHolding(s) in Company
23rd Sep 20138:33 amRNSHalf Yearly Report
19th Sep 20137:00 amRNSDate of Interim Announcement
30th Aug 20132:46 pmRNSHolding(s) in Company
21st Aug 20137:00 amRNSDirectorate Change
16th Aug 201312:29 pmRNSHolding(s) in Company
8th Aug 20137:00 amRNSAtu027 Phase I/II Update
12th Jul 20134:32 pmRNSHolding(s) in Company
3rd Jul 20137:00 amRNSCancellation of warrants
26th Jun 20132:47 pmRNSResult of AGM
26th Jun 20139:00 amRNSIssue of Options
26th Jun 20137:00 amRNSDirectorate Change
18th Jun 20137:00 amRNSAtu027 update: progression into Phase IIa
7th Jun 20134:35 pmRNSPrice Monitoring Extension
3rd Jun 20134:35 pmRNSPrice Monitoring Extension
3rd Jun 201311:30 amRNSNotice of AGM
29th May 20137:01 amRNSFinal Results
29th May 20137:00 amRNSDirectorate Change
2nd May 20134:52 pmRNSHolding(s) in Company
2nd May 20133:55 pmRNSHolding(s) in Company
2nd May 20133:52 pmRNSHolding(s) in Company
2nd May 20133:26 pmRNSHolding(s) in Company
29th Apr 201312:15 pmRNSResult of EGM
10th Apr 20137:00 amRNSPlacing and Share Consolidation
8th Mar 20137:00 amRNSExercise of warrants
5th Mar 20139:00 amRNSBusiness Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.